BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 33268401)

  • 1. Comparison of a progestin-primed ovarian stimulation protocol with a flexible GnRH antagonist protocol in patients with polycystic ovary syndrome who are participating in an IVF programme: study protocol for a randomised controlled trial.
    Wang N; Zhu Q; Ma M; Liang Z; Tao Y; Wang Y; Kuang Y
    BMJ Open; 2020 Dec; 10(12):e038153. PubMed ID: 33268401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
    Xiao ZN; Peng JL; Yang J; Xu WM
    Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of progestin-primed ovarian stimulation in women with polycystic ovary syndrome undergoing
    Yang L; Liang F; Yuan Y; Luo X; Wang Q; Yao L; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1224858. PubMed ID: 37795363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial.
    Wang Y; Kuang Y; Chen Q; Cai R
    Trials; 2018 Aug; 19(1):455. PubMed ID: 30134964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial.
    Zheng X; Guo W; Zeng L; Zheng D; Yang S; Xu Y; Wang L; Wang R; Mol BW; Li R; Qiao J
    Hum Reprod; 2022 Jan; 37(2):242-253. PubMed ID: 34849920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol.
    Huang TC; Huang MZ; Seow KM; Yang IJ; Pan SP; Chen MJ; Hwang JL; Chen SU
    Sci Rep; 2021 Nov; 11(1):22732. PubMed ID: 34815477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial.
    Wang Y; Chen Q; Wang N; Chen H; Lyu Q; Kuang Y
    Medicine (Baltimore); 2016 Mar; 95(9):e2939. PubMed ID: 26945402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
    Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
    Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.
    Kadoura S; Alhalabi M; Nattouf AH
    Sci Rep; 2022 Mar; 12(1):4456. PubMed ID: 35292717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome.
    Das M; Son WY; Buckett W; Tulandi T; Holzer H
    Reprod Biomed Online; 2014 Nov; 29(5):545-51. PubMed ID: 25262236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type.
    Lambalk CB; Banga FR; Huirne JA; Toftager M; Pinborg A; Homburg R; van der Veen F; van Wely M
    Hum Reprod Update; 2017 Sep; 23(5):560-579. PubMed ID: 28903472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison the effects of progestin-primed ovarian stimulation (PPOS) protocol and GnRH-a long protocol in patients with normal ovarian reserve function.
    Xu S; Wang X; Zhang Y; Han Y; Zhang C
    Gynecol Endocrinol; 2023 Dec; 39(1):2217263. PubMed ID: 37236243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progestin-primed milder stimulation with clomiphene citrate yields fewer oocytes and suboptimal pregnancy outcomes compared with the standard progestin-primed ovarian stimulation in infertile women with polycystic ovarian syndrome.
    Ye H; Tian H; He W; Lyu Q; Kuang Y; Chen Q; Sun L
    Reprod Biol Endocrinol; 2018 May; 16(1):53. PubMed ID: 29807533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cumulative live birth rates between progestin-primed ovarian stimulation protocol and gonadotropin-releasing hormone antagonist protocol in different populations.
    Zhou R; Dong M; Huang L; Wang S; Fan L; Liang X; Zhang X; Liu F
    Front Endocrinol (Lausanne); 2023; 14():1117513. PubMed ID: 37143731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial.
    Santos-Ribeiro S; Mackens S; Popovic-Todorovic B; Racca A; Polyzos NP; Van Landuyt L; Drakopoulos P; de Vos M; Tournaye H; Blockeel C
    Hum Reprod; 2020 Dec; 35(12):2808-2818. PubMed ID: 32964939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT).
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Alexopoulou E; Kolibianakis EM
    Hum Reprod; 2010 Mar; 25(3):683-9. PubMed ID: 20008886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LH on GnRH-ant day to basal LH affects the IVF/ICSI outcome of PCOS women undergoing GnRH-antagonist protocol.
    Wei Y; Luan T; Shen J; Zhang J; Zhang J; Su Y; Ling X; Li X; Zhao C
    Int J Gynaecol Obstet; 2024 Feb; 164(2):624-632. PubMed ID: 37724009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.